| Do structural differences in statins correlate with clinical efficacy? | |
| | |
MedLine Citation:
|
PMID: 20581679 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Statins, by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, decrease the synthesis not only of cholesterol but also of nonsteroidal mevalonate derivatives. While the first effect translates into plasma cholesterol reductions, the second is related to nonlipid-lowering (pleiotropic) properties. Purpose of this review is to assess the correlation between differences in statin structures and clinical effects. While the cardiovascular benefits of statin chronic therapy are achieved by lowering low-density lipoprotein cholesterol (LDL-C) and should be considered a class effect, the acute ones may reflect structure differences and pleiotropic properties of these drugs. RECENT FINDINGS: Clinical studies conducted in acute coronary syndrome patients suggest that some benefits achieved by early statin treatment could be related to their pleiotropic properties. Indeed, ex-vivo studies showed the ability of sera from hypercholesterolemic patients treated with a single dose of atorvastatin (but not of simvastatin), to inhibit smooth muscle cell proliferation, independently of LDL-C lowering. SUMMARY: These findings give a clinical ground to statins' potentially structure-related anti-inflammatory and pleiotropic properties, opening the possibility to control different aspects of atherosclerosis, by choosing the appropriate statin (tailored therapy), particularly in high-cardiovascular-risk patients. |
| | |
Authors:
|
Lorenzo Arnaboldi; Alberto Corsini |
Related Documents
:
|
3056429 - Effects of lovastatin alone and in combination with cholestyramine on serum lipids and ... 19331439 - Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol wi... 8875969 - Rationale for effective treatment of hypercholesterolemia. 21105969 - 'trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dy... 19029469 - Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a poo... 16082429 - Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet. 21367929 - Differential mirna expression in omental adipose tissue and in the circulation of obese... 8573359 - Ethnic differences in micronutrient intake in a rural biethnic population. 6705139 - Modification of the development of n-nitrosomorpholine-induced hepatic lesions by 2-ace... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current opinion in lipidology Volume: 21 ISSN: 1473-6535 ISO Abbreviation: Curr. Opin. Lipidol. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-13 Completed Date: 2010-10-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9010000 Medline TA: Curr Opin Lipidol Country: England |
Other Details:
|
Languages: eng Pagination: 298-304 Citation Subset: IM |
Affiliation:
|
Department of Pharmacological Sciences, Faculty of Pharmacy, Università degli Studi di Milano, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
drug therapy* Animals Cardiovascular System / drug effects*, metabolism Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry*, pharmacology, therapeutic use* Structure-Activity Relationship Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance.
Next Document: Acquired myasthenia gravis in childhood.